메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of
- 김갑성 기자
- 2025-07-28 07:33
Breakthrough in Light Therapy: KouShiCare utilizes DWV™LLLT Technology to Treat Dry Eyes

HONG KONG, July 27, 2025 -- KouShiCare, a leading innovator in healthcare technology, is proud to announce a groundbreaking advancement in the treatment of dry eye disease. The company's latest device harnesses the power of DWV™ Low-Level Laser Therapy (LLLT) technology, marking a significant step forward in light-based ocular care. Approximately 344 million people worldwide suffer from dry eye disease. This condition causes discomfort, blurred vision, and a significant decline in quality of life. Traditional treatments, like eye drops and medications, often offer only temporary relief
- 김갑성 기자
- 2025-07-27 23:07
Xinhua Silk Road: 중국 동부 도시 룽커우, 중국 내 지속 가능한 건강•웰니스 발전의 선두주자로 부상

[ 메디채널 김갑성 기자 ] 베이징 2025년 7월 27일 -- 중국 동부에 자리한 현급 도시 룽커우가 최근 발표된 '중국 건강•웰니스 산업 연례 보고서(2024-2025)'에서 '지속 가능한 발전 역량을 갖춘 건강•웰니스 산업 100대 현'에 선정됐다. 일찌감치 건강•웰니스 산업 육성에 착수한 룽커우는 산둥성에서 현 단위 노인 돌봄 서비스 시스템 혁신 및 건강•웰니스 기반 관광 시범 도시로 지정됐다. 현지 노인 돌봄 센터에서 5년째 거주 중인 99세 천펑린(Chen Fenglin)씨는 센터의 맛있는 식사, 세심하고 배려심 많은 의료진, 우수한 서비스 품질 덕분에 항상 편안함을 느낀다고 말한다. 센터 운영을 담당하는 한유(Han Yu)씨는 "노인이 행복하게 생활하게 만들겠다는 원칙에 따라 센터는 노인과 직원들 사이에 정서적 유대감을 조성해 노인들이 요양원에서 생활하더라도 자기 집처럼 편안하게 느낄 수 있도록 노력하고 있다"고 말했다. 이 센터는 룽커우가 의료와 노인 돌봄 등 다양한 분야를 통합해 발전을 도모하고 있음을 보여주는 대표적인 사례다. 최근 몇 년 동안 룽커우시의
- 김갑성 기자
- 2025-07-27 13:49
Xinhua Silk Road: E. China city Longkou moves to forefront of sustainable health & wellness dev. in China

BEIJING, July 26, 2025 -- Longkou, a county-level city in east China, has recently been included into China's top 100 counties by sustainable development capacity of health and wellness industry, according to the annual report on health and wellness industry of China (2024-2025). Longkou is an early starter in bolstering health and wellness industry. It is a demonstrative city for county-wide elderly care service system innovation and health and wellness-based tourism in Shandong Province. In a local elderly care center, 99-year-old Chen Fenglin, who has lived there for five yea
- 김갑성 기자
- 2025-07-26 19:24
중국에서 실시한 남성 성인형 탈모(AGA) 치료를 위한 KX-826 팅크제 1.0%에 대한 제2상 확증 임상시험에서 일차 평가변수 달성

[ 메디채널 김갑성 기자 ] 쑤저우, 중국 2025년 7월 26일 -- 킨토르 제약(Kintor Pharmaceutical Limited, 이하 '회사')이 자체 개발 중인 KX-826 팅크제 1.0%가 남성 성인형 탈모(AGA) 치료를 위한 제2상 확증 임상시험에서 탑라인 결과를 확보했다고 밝혔다. 이번 임상시험 결과, 제2상에서 통계적으로 유의하고 임상적으로 의미 있는 결과를 가진 일차 평가변수를 달성하면서 우수한 유효성과 안전성을 입증했다. 제2상에는 총 90명의 환자가 참여했으며, 분석 결과는 다음과 같다. 위약 그룹 대비 유효성 측면에서 0.5% BID(1일 2회)과 1.0% BID 그룹 모두 통계적으로 임상적으로 유의한 치료적 유효성과 임상 유의성을 보였다. 0.5% BID 그룹의 표적 부위 비솜털 수(TAHC)는 기준선 대비 22.39개/cm² 증가했다. 1.0% BID 그룹의 TAHC는 베이스라인 대비 21.87개/cm² 증가했다. 위약 그룹의 TAHC는 베이스라인 대비 8.73개/cm² 증가했다. 0.5% BID 그룹의 TAHC는 위약 그룹 대비 13.66개/cm² 증가해 통계적으로
- 김갑성 기자
- 2025-07-26 09:52
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 26, 2025 -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: Regarding efficacy, c
- 김갑성 기자
- 2025-07-26 07:30
Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has designated its Investigational New Drug SAP-001 as a Fast Track product for treatment of hyperuricemia in adult patients with gout who are refractory to conventional therapy. "We are excited about the Fast Track designation for SAP-001" says Dr. Wenfeng Miao, Shanton's CMO. "Refractor
- 김갑성 기자
- 2025-07-25 22:59
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 25, 2025 -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: Regarding efficacy, c
- 김갑성 기자
- 2025-07-25 20:30
Amcor announces registered exchange offers

ZURICH, July 25, 2025 -- Amcor plc ("Amcor") (NYSE: AMCR, ASX: AMC) today announced the commencement of offers (the "exchange offers") by Amcor Flexibles North America, Inc., Amcor's wholly-owned subsidiary (the "Issuer") and the guarantors, including Amcor (the "Guarantors"), to exchange: (1) up to $725,000,000 4.800% Guaranteed Senior Notes due 2028 (the "Old 2028 Notes") for a like principal amount of 4.800% Guaranteed Senior Notes due 2028, the offer of which has been registered under the Securities Act of 1933, as amended (the "Secur
- 황정호 기자
- 2025-07-25 20:12
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA'S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 25, 2025 -- The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, officiated the event, unveiling the campaign's logo and tagline, "Healing Meets Hospitality." MYMT 2026 aims to position Malaysia as a premier medical tourism destination by showcasing its advanced healthcare services and hospitality. The campaign also seeks to attract internat
- 김갑성 기자
- 2025-07-25 14:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-07_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 07일 19시 40분